Anis Hamid

Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer

Anis Hamid, Kathryn P. Gray, Grace Shaw et al. · European Urology · 2018 · 269 citations

Medicine, Molecular Genetics, Oncology +16

EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer

Katherine L. Morel, Anjali V. Sheahan, Deborah L. Burkhart et al. · Nature Cancer · 2021 · 241 citations · Full text

Medicine, Molecular Biology, Oncology +12

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet Oncology · 2023 · 199 citations

Medicine, Oncology, Pharmacology +16

LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).

Shahneen Sandhu, Anthony M. Joshua, Louise Emmett et al. · Journal of Clinical Oncology · 2023 · 78 citations

Medicine, Nuclear Medicine, Pharmacology +17

Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry

Edoardo Francini, Kathryn P. Gray, Grace Shaw et al. · Prostate Cancer and Prostatic Diseases · 2019 · 76 citations · Full text

Medicine, Oncology, Urology +16